Back

Vericiguat in a real-world heart failure population: a single-centre experience

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Vericiguat, SGLT2 inhibitors and implementation Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Carlos Palacios-Castello

UNIVERSITY HOSPITAL VIRGEN DEL ROCIO, Seville (Spain)

6 More presentations in this session

Presentation thumbnail
A placebo-correcetd effect of the initial eGFR decline following SGLT-2 inhibitor initiation: a systematic review and meta-analysis
Doctor S. Urban (Lubin, PL)
Abstract Slides Video
Presentation thumbnail
Scarred for life - outcomes of ischaemic and non-ischaemic cardiomyopathy after heart failure optimisation
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video
Presentation thumbnail
Estimated multinational budget impact of empagliflozin for heart failure patients with full spectrum of left ventriclular ejection fraction
Doctor E. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Quantifying the burden of potentially inappropriate prescribed medicines among people hospitalised with heart failure in Australia: a comparison with ESC recommendations
Associate Professor M. Falster (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
The effect of dapagliflozin on the microvascular endothelial cell function and metabolism in patients with heart failure: a preliminary report
Doctor M. Tarnawska (Gdansk, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Vericiguat, SGLT2 inhibitors and implementation

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Initial experience of vericiguat treatment in patients with heart failure and high risk of decompensation.
thumbnail
Congress Presentation
Incidence of cardiovascular events following vericiguat initiation in patients with heart failure with or without a recent worsening heart failure event: a hospital-based real-world cohort study
thumbnail
Congress Presentation
Initial experience with vericiguat treatment in real life. VERITA registry versus the VICTORIA study.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources